See more : Pan Asia Footwear Public Company Limited (PAF.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Xtant Medical Holdings, Inc. (XTNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Xtant Medical Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Mack-Cali Realty Corporation (CLI) Income Statement Analysis – Financial Results
- Glodon Company Limited (002410.SZ) Income Statement Analysis – Financial Results
- Guskin Gold Corp. (GKIN) Income Statement Analysis – Financial Results
- Hubtown Limited (HUBTOWN.BO) Income Statement Analysis – Financial Results
- AltaGas Ltd. (AGEEF) Income Statement Analysis – Financial Results
Xtant Medical Holdings, Inc. (XTNT)
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 91.30M | 57.97M | 55.26M | 53.34M | 64.68M | 72.20M | 82.61M | 90.00M | 59.35M | 35.33M | 33.07M | 32.98M | 30.15M | 15.42M | 7.39M | 459.23K |
| Cost of Revenue | 35.84M | 25.83M | 22.77M | 18.95M | 22.17M | 28.72M | 32.51M | 27.71M | 20.26M | 13.03M | 14.19M | 10.34M | 9.11M | 3.36M | 2.32M | 386.48K |
| Gross Profit | 55.47M | 32.14M | 32.49M | 34.39M | 42.52M | 43.49M | 50.10M | 62.29M | 39.08M | 22.30M | 18.89M | 22.64M | 21.04M | 12.05M | 5.08M | 72.75K |
| Gross Profit Ratio | 60.75% | 55.44% | 58.79% | 64.48% | 65.73% | 60.23% | 60.65% | 69.21% | 65.86% | 63.11% | 57.11% | 68.66% | 69.79% | 78.18% | 68.65% | 15.84% |
| Research & Development | 1.34M | 915.00K | 870.00K | 657.00K | 932.00K | 1.70M | 2.44M | 3.41M | 2.55M | 1.44M | 572.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 25.85M | 15.46M | 14.45M | 13.50M | 17.94M | 13.00M | 15.33M | 16.03M | 13.24M | 9.02M | 10.77M | 11.56M | 8.23M | 11.14M | 0.00 | 0.00 |
| Selling & Marketing | 38.44M | 22.52M | 21.03M | 20.98M | 25.84M | 32.06M | 40.51M | 44.06M | 28.73M | 16.91M | 16.02M | 15.62M | 18.50M | 8.90M | 0.00 | 0.00 |
| SG&A | 64.29M | 37.98M | 35.47M | 34.49M | 43.78M | 45.06M | 55.84M | 60.09M | 41.97M | 25.93M | 26.79M | 27.18M | 26.74M | 20.03M | 4.16M | 88.59K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 58.00K | 3.00K | -74.71K | -351.91K | 388.18K | -318.84K | 92.65K | -1.56M | 755.39K | 633.83K | 72.30K | 88.59K |
| Operating Expenses | 65.63M | 38.89M | 36.34M | 35.14M | 44.77M | 50.88M | 63.77M | 68.44M | 48.34M | 27.65M | 27.17M | 27.59M | 27.49M | 20.67M | 8.70M | 88.59K |
| Cost & Expenses | 101.46M | 64.72M | 59.12M | 54.09M | 66.94M | 79.60M | 96.28M | 96.15M | 68.60M | 40.68M | 41.35M | 37.92M | 36.60M | 24.03M | 11.02M | 475.07K |
| Interest Income | 149.00K | 31.00K | 995.00K | 5.98M | 5.77M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.04K | 12.99K | 0.00 |
| Interest Expense | 2.94M | 1.69M | 995.00K | 5.98M | 5.77M | 10.15M | 14.70M | 12.26M | 7.73M | 5.66M | 4.65M | 1.86M | 1.16M | 1.65M | 513.93K | 0.00 |
| Depreciation & Amortization | 3.17M | 1.30M | 1.34M | 2.10M | 3.20M | 5.74M | 8.39M | 7.24M | 4.89M | 952.32K | 377.52K | 782.89K | 755.39K | 682.54K | 707.93K | 0.00 |
| EBITDA | 5.07M | -5.43M | -2.51M | 1.33M | 850.00K | -54.22M | -29.31M | 61.43K | -7.09M | -3.90M | -7.29M | -5.07M | -1.09M | -17.14M | -2.90M | -15.85K |
| EBITDA Ratio | 5.56% | -9.37% | -4.56% | 2.49% | 1.22% | -1.11% | -6.46% | 0.83% | -6.70% | -13.36% | -23.61% | -19.49% | -18.89% | -51.44% | -39.28% | -3.45% |
| Operating Income | -10.16M | -6.76M | -3.85M | -751.00K | -2.35M | -60.08M | -37.83M | -7.55M | -12.08M | -6.26M | -9.01M | -4.94M | -6.45M | -8.61M | -3.62M | -15.85K |
| Operating Income Ratio | -11.13% | -11.65% | -6.97% | -1.41% | -3.64% | -83.21% | -45.80% | -8.38% | -20.35% | -17.73% | -27.24% | -14.99% | -21.39% | -55.87% | -49.00% | -3.45% |
| Total Other Income/Expenses | 9.12M | -1.66M | -995.00K | -5.98M | -5.87M | -10.02M | -14.58M | -11.90M | -7.63M | -4.24M | -3.69M | -2.77M | 3.44M | -10.85M | 3.63M | 0.00 |
| Income Before Tax | -1.04M | -8.42M | -4.85M | -6.73M | -8.12M | -70.10M | -52.41M | -19.44M | -19.71M | -10.51M | -12.69M | -7.71M | -3.01M | -19.47M | -4.13M | -15.85K |
| Income Before Tax Ratio | -1.14% | -14.52% | -8.77% | -12.61% | -12.56% | -97.09% | -63.44% | -21.60% | -33.22% | -29.74% | -38.38% | -23.39% | -9.97% | -126.27% | -55.80% | -3.45% |
| Income Tax Expense | -1.70M | 69.00K | 995.00K | 296.00K | 98.00K | 124.00K | 14.63M | 50.36K | -17.54M | 5.34M | 4.75M | 306.26K | 1.16M | 1.65M | 1.83K | 0.00 |
| Net Income | 660.00K | -8.49M | -5.84M | -7.02M | -8.22M | -70.10M | -52.41M | -19.49M | -2.17M | -10.51M | -12.69M | -7.71M | -3.01M | -19.47M | -4.13M | -15.85K |
| Net Income Ratio | 0.72% | -14.64% | -10.57% | -13.17% | -12.71% | -97.09% | -63.44% | -21.66% | -3.66% | -29.74% | -38.38% | -23.39% | -9.97% | -126.27% | -55.80% | -3.45% |
| EPS | 0.01 | -0.09 | -0.07 | -0.25 | -0.62 | -5.97 | -34.76 | -18.46 | -2.62 | -19.26 | -29.15 | -19.83 | -8.43 | -66.03 | -17.02 | -0.07 |
| EPS Diluted | 0.01 | -0.09 | -0.07 | -0.25 | -0.62 | -5.93 | -34.51 | -18.32 | -2.62 | -19.26 | -29.15 | -19.83 | -8.43 | -66.03 | -17.02 | -0.07 |
| Weighted Avg Shares Out | 119.09M | 94.09M | 85.46M | 28.50M | 13.16M | 11.74M | 1.51M | 1.06M | 829.71K | 545.55K | 435.49K | 388.91K | 356.83K | 294.83K | 242.40K | 242.40K |
| Weighted Avg Shares Out (Dil) | 126.79M | 94.09M | 85.46M | 28.50M | 13.16M | 11.83M | 1.52M | 1.06M | 829.71K | 545.55K | 435.49K | 388.91K | 356.83K | 294.83K | 242.40K | 242.40K |
Xtant Medical Holdings, Inc. (XTNT) Q3 2024 Earnings Conference Call Transcript
Xtant Medical Reports Third Quarter 2024 Financial Results
Xtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select Conference
Xtant Medical to Issue Third Quarter 2024 Financial Results on November 12, 2024
Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System
Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus
Xtant Medical Holdings, Inc. (XTNT) Q2 2024 Earnings Call Transcript
Xtant Medical Announces Closing of $5.0 Million Private Placement
Xtant Medical Announces $5.0 Million Private Placement
Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024
Source: https://incomestatements.info
Category: Stock Reports
What were the key drivers of Xtant Medical’s revenue growth in 2024?
The increase is primarily due to the contribution of additional sales resulting from the acquisition of the Surgalign Holdings’ hardware and biologics business, greater independent agent sales and additional Coflex and CoFix product sales.
How did Xtant Medical’s gross margin change in Q3 2024?
Gross margin for the third quarter of 2024 was 58.4%, compared to 61.3% for the prior year quarter. The decrease is primarily due to reduced production throughput, partially offset by additional scale.